Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA

NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...

Related Keywords

New York ,United States ,Americans ,American ,Herriot Tabuteau ,Axsome Mo ,Mark Jacobson ,Centers For Disease ,American Migraine Foundation ,Axsome Therapeutics Inc ,World Health Organization ,Drug Administration ,Nasdaq ,New Drug Application ,Complete Response Letter ,Chief Executive Officer ,Disease Control ,American Migraine ,Molecular Solubility Enhanced Inclusion Complex ,Axsome Therapeutics ,Nasdaq Axsm ,Nc ,Xs 07 ,Migraine ,Fda ,Axsome ,Axsm ,Neuroscience ,Ns ,